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branching technique for the stent graft
placement still carries some morbidity and
mortality risk. The optimal use of endovas-
cular stent graft for mycotic aortic aneurysm
needs to be clarified in further studies.
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Grey zone area for Glenn and
future Fontan candidates
To the Editor:
We enjoyed the very good article by
Scheurer and colleagues.1 We have a few
comments.
Inhaled nitric oxide produces significant
reduction in Glenn pressures and improve-
ment in systemic perfusion and pulmonary
gas exchange in patients with marked in-
creases of Glenn pressures after bidirec-
tional Glenn anastomosis. Patients who do
not respond should be investigated for an
anatomic lesion.2
Glenn shunt mortality was higher with
surgical intervention before age 120 days
but was not affected by surgical intervention
during the respiratory virus season. Opera-
tions in the youngest age groups might
adversely affect mortality.3
There were no differences in morbidity
and mortality outcomes after the bidirec-
tional Glenn operation between the Nor-
wood-Right ventricle to pulmonary artery
andNorwood-Blalock Taussig Shunt groups.
Despite younger age at presentation, the
Norwood-Right ventricle to pulmonary
artery patients had better growth rate, which
might have contributed to the similar post-
operative outcomes.4
Atrial septal defects should be left open
for all patients with severe right heart hypo-
plasia and in patients with postbypass right
atrial pressures of more than 12 mm Hg.5
The advantages of incorporating a hypo-
plastic ventricle to partly support the pulmo-
nary circulation are the following: (1) ability
to increase the cardiac output; (2) adaptation
to exercise; (3) maintenance of pulsatile
flow in the pulmonary circulation; (4) flex-
ibility to increased pulmonary vascular
resistance; (5) circulation at low venous
pressure in the Inferior Vena Cava system;
and (6) capability of a hypoplastic right
heart to adequately handle the reduced
preload.6
There is a major debate for the gray-zone
high-risk patients who do not fulfill the
Choussat commandments. The current pro-
tocol in those patients is first to review all
the data in detail. Full consideration is given
as to whether there are any surgically (or in-
terventionally) correctable lesions, such as
atrioventricular valve regurgitation amena-
ble to repair or isolated stenoses or hypopla-
sia within the central pulmonary arteries.
Ventricular function, if impaired, might be
optimized by altering medical management
(vasodilators, diuretic therapy, and trial of
oral enoximone, if appropriate). Evidence
of increased pulmonary vascular resistance
is treated with a course of pulmonary vaso-
dilator therapy (sildenafil or bosentan). The
patients are then reassessed for suitability
for Fontan completion. The evidence would
suggest that only 2 of the original 10 com-
mandments of Choussat carry significant
weight for both early and late outcome
over the Fontan procedure and that they
are preoperative ventricular function and
preoperative pulmonary artery pressures of
greater than 15 mm Hg.7
We found that right ventricular mor-
phology; single ventricle; intact septum;
semilunar valve abnormalities; diastolic
dysfunction; myocardial hypertrophy, dila-
tation, or both; older age; bilateral superior
vena cavae; pulmonary airway disease; and
hypotonia all carry a worse prognosis and
a tough postoperative course.
To be right ventricular morphology;
single ventricle; intact septum; semilunar
valve abnormalities; diastolic dysfunction;
myocardial hypertrophy, dilatation, or
both; older age; bilateral superior vena
cavae; Interrupted IVC; pulmonary airway
disease; and hypotonia all carry a worse
prognosis and a tough postoperative
course.
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To the Editor:
I read with great interest the article by Hager
and associates1 on coarctation repair. The
authors note that the majority of patients re-
mained hypertensive in the long term, even
after coarctation repair. This very interesting
phenomena, however, has to be examined in
the mirror of the little known fact that most
patients are often hypertensive below the
level of the coarctation even before the
coarctation is repaired! While pressure
measurements indeed show significantly
higher pressures above the coarctation, the
mean arterial pressure below the coarcta-
tion is also higher than that of an average
normal subject. Thus, arterial hypertensionar Surgery c Volume 135, Number 6 1405
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Baumgartner C, Busch R, Kostolny M,
et al. Impaired Elastic Properties of the
Ascending Aorta in Newborns Before and
Early After Successful Coarctation Repair:
Proof of a Systemic Vascular Disease of the
ventricularis, spongiosa, and fibrosa of the
leaflets. Additionally, a significant increase
of both transvalvular and distal gradients
were recorded at 4-month follow-up echo-
cardiographic analysis. On the contrary,
scaffolds repopulated with mesenchymal
stem cells did not evidence either degenera-
tive notes or inflammatory reactions.
These findings might suggest ‘‘the onset
of a structural deterioration of the scaffold in
the [bone marrow–derived mononuclear
cell] group and a protective effect of the
injections of [mesenchymal stem cells].’’1
We are concerned that such conclusions
seem audacious because the study suffers
from a main limitation represented by the
cell-seeding modality. In fact, the authors,
looking for an answer to question number
2, choose to inject the cells directly into
Letters to the Editorobserved after coarctation repair is not a new
phenomenon, but is simply the continuation
of the neurosympathetic process that existed
before the coarctation repair.
Francis Robicsek, MD, PhD
Carolinas Heart Institute
Carolinas Medical Center
Charlotte, NC 28203
Reference
1. Hager A, Kanz S, Kaemmerer H, Schreiber C,
Hess J. Coarctation Long-term Assessment
(COALA): significance of arterial hyperten-
sion in a cohort of 404 patients up to 27 years
after surgical repair of isolated coarctation of
the aorta, even in the absence of restenosis
and prosthetic material. J Thorac Cardiovasc
Surg. 2007;134:738-45.
doi:10.1016/j.jtcvs.2007.11.053Reply to the Editor:
Robicsek outlined in his letter to the Editor
in response to our article1 that arterial hyper-
tension exists distal the coarctation even
before coarctation repair. Hypertension in
the long-term follow-up is simply the con-
tinuation of this neurosympathetic process.
Previously published data from our
group2 on blood pressure and aortic disten-
sibility in neonates with coarctation before
and after surgical repair did not show
poststenotic hypertension before repair in
general. However, we totally agree with
Robicsek and other authors3,4 that inborn
processes not touched by current modes of
repair are also responsible for hypertension
in the long-term follow-up after successful
repair. We believe that the starting point of
the pathophysiologic chain is the inborn
alteration of the arterial wall with elastic fi-
ber fragmentation, fibrosis, and cystic me-
dial necrosis, which are later exaggerated
by existing hypertension. This causes the in-
creased stiffness most pronounced in the
central elastic arteries, the blunted barore-
ceptor reflex, and the neurosympathetic acti-
vation. However, the novelty of our study
was the extent of this phenomenon. Our
relation to age showed that arterial hyperten-
sion has to be expected in almost all patients
after coarctation repair in older ages. Close
surveillance and aggressive treatment of
arterial hypertension might prevent further
cardiovascular disease.
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Heart valve tissue engineering:
Research should proceed along
validated routes
To the Editor:
In their article focusing on in vivo autolo-
gous recellularization of a tissue-engineered
heart valve, Vincentelli and colleagues1
raise 2 main questions: (1) Which are the
best candidates for scaffold repopulation?
(2) Does direct injection of cells into the
scaffold guarantee adequate cellular recolo-
nization?
According to the cell type chosen for
scaffold seeding, the adoption of nonse-
lected bone marrow–derived mononuclear
cells was associated with early degeneration
with thickening and retraction of the cusps,
growth of fibrotic pannus along the suture
lines, and thickening and calcification of
the wall conduits. Histologically, a marked
inflammatory response with extracellular
matrix disarray and macrophage infiltration
both in the adventitia and the media layers
were observed, along with a loss of the
proper collagen allocation between the
the decellularized scaffold (onto the conduit
walls and valve annulus, excluding the
leaflets), instead of adopting a biomimetic
environment.
The adoption of this alternative tech-
nique,which has been derived from themyo-
cardial setting,2 represents an innovative
concept for the valvular field and therefore
requires a careful validation. Fluorescent
cell tracking, which was performed on 4 of
14 animals in the first postoperative week,
evidenced, on day 1, the cell persistence
onto the injection site and, on day 7, a few
scattered cells into the matrix, the arterial
wall, and the leaflets. Moreover, nonlabeled
cells of host origin were found.
Is this enough to say that ‘‘in situ injec-
tion of bone marrow cells into a porcine
decellularized scaffold before implantation
enhanced the in vivo recolonization and
induced full re-endothelization’’?1 First,
endothelialization and scaffold repopulation
do not coincide. Even bioprostheses un-
dergo an endothelialization process of the
inert components once implanted. Second,
the process of repopulation implies an
architectural and hierarchic cell-specific
distribution along the leaflet’s ventricularis,
spongiosa, and fibrosa,3 which was not
observed in this experience.
In the article’s ‘‘Discussion’’ section, the
authors themselves affirm that they had no
direct evidence that cells would grow inside
the matrix. According to the hypothesis that
injected cells might enhance autologous
recellularization, further evidence is needed
to draw definite conclusions, and the pro-
vided results do not concretely support the
initial hypothesis.
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